CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Caribou Biosciences, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $9.48M | $9.27M | $32.77M | $13.30M | $8.91M | $12.00M | $5.35M | 84.9% | +2.2% |
| Rest of world | $1.68M | $724.00K | $1.71M | $548.00K | $685.00K | $358.00K | $439.00K | 15.1% | +132.2% |
From the segment and revenue-disaggregation notes of Caribou Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.